嗜酸性气道疾病负担:重度哮喘、慢阻肺与哮喘-慢阻肺重叠的比较
该研究汇总气道疾病多维评估研究数据,比较哮喘-慢阻肺重叠(ACO,n=106)、重度哮喘(n=64)和单纯慢阻肺(n=153)患者的疾病负担。以血嗜酸性粒细胞≥0.3×10^9/L定义嗜酸性气道疾病,ACO中占55%、重度哮喘44%、慢阻肺29%。嗜酸性与非嗜酸性患者疾病负担相似,嗜酸性ACO的群体累积负担更高。
要点
- 血嗜酸性粒细胞≥0.3×10^9/L时,ACO中嗜酸性表型占55%。
- 嗜酸性与非嗜酸性气道疾病的疾病负担相似,健康相关生活质量均较差。
- 嗜酸性ACO因患病率高,群体累积疾病负担大于嗜酸性重度哮喘和慢阻肺。
核心结论
- 嗜酸性ACO、嗜酸性重度哮喘和嗜酸性慢阻肺的疾病负担均高,其中ACO的群体累积负担尤为突出。
- 重度患者的疾病负担可能由气道炎症以外的因素驱动。
研究设计与样本
- 汇总气道疾病多维评估研究的参与者,横断面评估人口学和临床特征。
- 纳入ACO患者106例、重度哮喘64例、单纯慢阻肺153例。
主要发现
- 以血嗜酸性粒细胞≥0.3×10^9/L定义,41%患者为嗜酸性气道疾病:ACO 55%、重度哮喘44%、慢阻肺29%。
- 血嗜酸性粒细胞与痰嗜酸性粒细胞中度相关(rs=0.51,n=257,P<0.001)。
- 嗜酸性与非嗜酸性气道疾病的疾病负担相似,健康相关生活质量差且过去一年急性加重次数多。
- 嗜酸性重度哮喘、慢阻肺和ACO之间的疾病负担相似。
- 嗜酸性慢阻肺的健康状况倾向于比嗜酸性ACO和重度哮喘更差,但ACO的群体累积负担更大。
关键数值与推荐
- 嗜酸性气道疾病定义为血嗜酸性粒细胞计数≥0.3×10^9/L。
- 血嗜酸性粒细胞≥0.3×10^9/L时各疾病嗜酸性表型比例:ACO 55%、重度哮喘44%、慢阻肺29%。
- 血与痰嗜酸性粒细胞相关系数rs=0.51(n=257,P<0.001)。
临床怎么用
- 临床可用血嗜酸性粒细胞≥0.3×10^9/L识别嗜酸性气道疾病患者。
- 对嗜酸性ACO、重度哮喘和慢阻肺均应关注高疾病负担,包括生活质量差和频繁急性加重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There is less understanding of phenotypes and disease burden in asthma-COPD overlap (ACO) than either disease alone. Blood eosinophils may help identify the patients in the clinic with eosinophilic airway inflammation. The potential value of this approach requires an understanding of the illness burden associated with eosinophilic ACO, eosinophilic severe asthma and eosinophilic COPD, defined by blood eosinophils. METHODS: Participants from studies of multidimensional assessment in airway disease were pooled to identify patients with ACO (n = 106), severe asthma (n = 64) and COPD alone (n = 153). Patients were assessed cross-sectionally for demographic and clinical characteristics, including disease burden indicators such as health-related quality of life (HRQoL) and past-year exacerbation. Eosinophilic patients were identified using different thresholds of blood eosinophil count. RESULTS: Using a blood eosinophil count ≥0.3 × 109 /L, 41% had eosinophilic airway disease: 55% in ACO, 44% in severe asthma and 29% in COPD. Blood and sputum eosinophils were moderately correlated (rs = 0.51, n = 257, P < 0.001). Burden of disease was similar between eosinophilic and non-eosinophilic airway diseases, with poor HRQoL and high number of past-year exacerbations. Burden of disease was similar across eosinophilic severe asthma, COPD and ACO. Eosinophilic COPD tended to have poorer health status than eosinophilic ACO and severe asthma; however, in context of a high prevalence of eosinophilic ACO, cumulative population-level burden of eosinophilic disease was greater in ACO. CONCLUSION: Disease burden across eosinophilic ACO, eosinophilic severe asthma and eosinophilic COPD was high, particularly cumulative population-level burden in ACO. Factors beyond airway inflammation may drive disease burden in severe patients.
引用
- Hiles SA, Gibson PG, McDonald VM, et al. Disease burden of eosinophilic airway disease: Comparing severe asthma, COPD and asthma-COPD overlap. Respirology. 2020. PMID: 32428971. doi:10.1111/resp.13841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。